People with head and neck cancer or leukemia in England are set to miss out on access to two new cancer drugs, after the National Institute for Health and Care Excellence (NICE) said it couldn’t recommend pembrolizumab (Keytruda) or gilteritinib (Xospata) for NHS use.
Read More
Health Rss 